| Pleasant Manor Nursing & Rehab | |
| 950 Homestead, Ashdown, Arkansas 71822 | |
| (870) 898-5001 | |
| Name | Pleasant Manor Nursing & Rehab |
|---|---|
| Location | 950 Homestead, Ashdown, Arkansas |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 88 |
| Occupancy Rate | 69.32% |
| Medicare ID (CCN) | 045227 |
| Legal Business Name | Pleasant Manor Nursing & Rehab |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1447530464 |
| Organization Name | PLEASANT MANOR NURSING & REHAB |
| Doing Business As | JLP INVESTMENTS LLC |
| Address | 950 Homestead Dr, Ashdown, AR 71822 |
| Phone Number | 870-898-5001 |
News Archive
Studies led by cell biologist Thomas Maresca at the University of Massachusetts Amherst are revealing new details about a molecular surveillance system that helps detect and correct errors in cell division that can lead to cell death or human diseases. Findings are reported in the current issue of the Journal of Cell Biology.
On Wednesday, September 19, the American College of Rheumatology and the Arthritis Foundation will jointly brief members of Congress and their staffs about the devastating effects of arthritis and related rheumatic diseases.
ASHP, together with five other healthcare organizations, today sent a letter to Reps. Morgan Griffith and Diana DeGette - the Vice Chairman and Ranking Member, respectively, of the House Energy and Commerce Subcommittee on Oversight and Investigations - asking Congress to take immediate action to address the public health crisis caused by persistent shortages of critical medications.
Salix Pharmaceuticals, Ltd. today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Crofelemer for the proposed treatment of HIV-associated diarrhea.
› Verified 6 days ago
| NPI Number | 1568469930 |
| Organization Name | PLEASANT MANOR NURSING HOME LLC |
| Address | 950 Homestead Dr, Ashdown, AR 71822 |
| Phone Number | 870-898-5001 |
News Archive
Studies led by cell biologist Thomas Maresca at the University of Massachusetts Amherst are revealing new details about a molecular surveillance system that helps detect and correct errors in cell division that can lead to cell death or human diseases. Findings are reported in the current issue of the Journal of Cell Biology.
On Wednesday, September 19, the American College of Rheumatology and the Arthritis Foundation will jointly brief members of Congress and their staffs about the devastating effects of arthritis and related rheumatic diseases.
ASHP, together with five other healthcare organizations, today sent a letter to Reps. Morgan Griffith and Diana DeGette - the Vice Chairman and Ranking Member, respectively, of the House Energy and Commerce Subcommittee on Oversight and Investigations - asking Congress to take immediate action to address the public health crisis caused by persistent shortages of critical medications.
Salix Pharmaceuticals, Ltd. today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Crofelemer for the proposed treatment of HIV-associated diarrhea.
› Verified 6 days ago
| NPI Number | 1962772806 |
| Organization Name | J.L.P. INVESTMENTS, LLC |
| Doing Business As | PLEASANT MANOR NURSING & REHAB |
| Address | 950 Homestead Dr, Ashdown, AR 71822 |
| Phone Number | 870-898-5001 |
News Archive
Studies led by cell biologist Thomas Maresca at the University of Massachusetts Amherst are revealing new details about a molecular surveillance system that helps detect and correct errors in cell division that can lead to cell death or human diseases. Findings are reported in the current issue of the Journal of Cell Biology.
On Wednesday, September 19, the American College of Rheumatology and the Arthritis Foundation will jointly brief members of Congress and their staffs about the devastating effects of arthritis and related rheumatic diseases.
ASHP, together with five other healthcare organizations, today sent a letter to Reps. Morgan Griffith and Diana DeGette - the Vice Chairman and Ranking Member, respectively, of the House Energy and Commerce Subcommittee on Oversight and Investigations - asking Congress to take immediate action to address the public health crisis caused by persistent shortages of critical medications.
Salix Pharmaceuticals, Ltd. today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Crofelemer for the proposed treatment of HIV-associated diarrhea.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Studies led by cell biologist Thomas Maresca at the University of Massachusetts Amherst are revealing new details about a molecular surveillance system that helps detect and correct errors in cell division that can lead to cell death or human diseases. Findings are reported in the current issue of the Journal of Cell Biology.
On Wednesday, September 19, the American College of Rheumatology and the Arthritis Foundation will jointly brief members of Congress and their staffs about the devastating effects of arthritis and related rheumatic diseases.
ASHP, together with five other healthcare organizations, today sent a letter to Reps. Morgan Griffith and Diana DeGette - the Vice Chairman and Ranking Member, respectively, of the House Energy and Commerce Subcommittee on Oversight and Investigations - asking Congress to take immediate action to address the public health crisis caused by persistent shortages of critical medications.
Salix Pharmaceuticals, Ltd. today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Crofelemer for the proposed treatment of HIV-associated diarrhea.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $16205 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 18.75 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.42 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 32.35 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.5 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.38 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.64 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.91 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 78.1 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 5.56 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 16.14 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 26.64 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.79 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.91 | 95.98 |